Assignee
INNATE PHARMA
FR·57 granted patents·56 pending applications·311 citations·filing 2006–2025
Top patents by PatentIndex Score
113 records- 0197US9717803B2Enzymatic conjugation of polypeptidesINNATE PHARMA·Filed 2012·Granted Aug 1, 2017·29 cites·40 claims
- 0296US11958907B2CD73 blockadeINNATE PHARMA·Filed 2020·Granted Apr 16, 2024·4 cites·21 claims
- 0396US10675359B2Enzymatic conjugation of antibodiesINNATE PHARMA·Filed 2017·Granted Jun 9, 2020·11 cites·24 claims
- 0496US9764038B2Enzymatic conjugation of antibodiesINNATE PHARMA·Filed 2012·Granted Sep 19, 2017·38 cites·13 claims
- 0595US11891444B2Variable regions for NKp46 binding proteinsINNATE PHARMA·Filed 2021·Granted Feb 6, 2024·3 cites·15 claims
- 0695US11572410B2Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2020·Granted Feb 7, 2023·3 cites·5 claims
- 0795US10329348B2Treatment of cancers using anti-NKG2A agentsINNATE PHARMA·Filed 2015·Granted Jun 25, 2019·16 cites·15 claims
- 0894US11267897B2Multispecific NK engager proteinINNATE PHARMA·Filed 2018·Granted Mar 8, 2022·8 cites·19 claims
- 0994US10577419B2KIR3DL2 binding agentsINNATE PHARMA·Filed 2015·Granted Mar 3, 2020·15 cites·10 claims
- 1094US10434180B2Enzymatic conjugation of polypeptidesINNATE PHARMA·Filed 2016·Granted Oct 8, 2019·20 cites·13 claims
- 1194US9427478B2Enzymatic conjugation of polypeptidesINNATE PHARMA·Filed 2014·Granted Aug 30, 2016·30 cites·21 claims
- 1293US10711063B2Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2015·Granted Jul 14, 2020·8 cites·13 claims
- 1393US10113003B2Multispecific NK engager proteinsINNATE PHARMA·Filed 2016·Granted Oct 30, 2018·15 cites·28 claims
- 1492US10676523B2Treatment regimens using anti-NKG2A antibodiesINNATE PHARMA·Filed 2015·Granted Jun 9, 2020·7 cites·10 claims
- 1591US11066470B2Humanized antibodies with increased stabilityINNATE PHARMA·Filed 2019·Granted Jul 20, 2021·3 cites·13 claims
- 1690US11078275B2Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphomaINNATE PHARMA·Filed 2019·Granted Aug 3, 2021·3 cites·12 claims
- 1790US10280222B2Humanized antibodies with increased stabilityINNATE PHARMA·Filed 2015·Granted May 7, 2019·8 cites·7 claims
- 1890US10174112B2Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphomaINNATE PHARMA·Filed 2017·Granted Jan 8, 2019·9 cites·12 claims
- 1989US11692039B2Multifunctional natural killer (NK) cell engagers binding to NKp46 and CD123INNATE PHARMA·Filed 2021·Granted Jul 4, 2023·2 cites·22 claims
- 2089US11377503B2Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptideINNATE PHARMA·Filed 2019·Granted Jul 5, 2022·3 cites·13 claims
- 2189US10870700B2Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2017·Granted Dec 22, 2020·6 cites·16 claims
- 2289US10766966B2CD73 blockadeINNATE PHARMA·Filed 2015·Granted Sep 8, 2020·5 cites·12 claims
- 2389US10246510B2KIR3DL2 binding agentsINNATE PHARMA·Filed 2013·Granted Apr 2, 2019·9 cites·20 claims
- 2488US11858990B2KIR3DL2 binding agentsINNATE PHARMA·Filed 2020·Granted Jan 2, 2024·2 cites·7 claims
- 2588US11001629B2Variable regions for NKp46 binding proteinsINNATE PHARMA·Filed 2016·Granted May 11, 2021·7 cites·6 claims
- 2688US9828427B2Anti-KIR3D antibodiesINNATE PHARMA·Filed 2015·Granted Nov 28, 2017·9 cites·7 claims
- 2787US11225519B2Treatment of cancers using anti-NKG2A agentsINNATE PHARMA·Filed 2019·Granted Jan 18, 2022·3 cites·18 claims
- 2887US11078274B2Siglec neutralizing antibodiesINNATE PHARMA·Filed 2017·Granted Aug 3, 2021·3 cites·23 claims
- 2987US2025092130A1Compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphomaINNATE PHARMA·Filed 2024·Application pending·0 cites
- 3086US10519234B2NKp46 binding proteinsINNATE PHARMA·Filed 2015·Granted Dec 31, 2019·6 cites·12 claims
- 3185US11208480B2Multispecific antigen binding proteinsINNATE PHARMA·Filed 2015·Granted Dec 28, 2021·3 cites·8 claims
- 3284US2024368281A1Treatment regimens using anti-nkg2a antibodiesINNATE PHARMA·Filed 2024·Application pending·0 cites
- 3383US11130817B2CD73 blocking agentsINNATE PHARMA·Filed 2016·Granted Sep 28, 2021·3 cites·5 claims
- 3483US10071169B2Enzymatic conjugation of polypeptidesINNATE PHARMA·Filed 2014·Granted Sep 11, 2018·3 cites·27 claims
- 3583US10036010B2Recognition tags for TGase-mediated conjugationINNATE PHARMA·Filed 2013·Granted Jul 31, 2018·4 cites·8 claims
- 3682US10344087B2Treatment of peripheral T cell lymphomaINNATE PHARMA·Filed 2014·Granted Jul 9, 2019·3 cites·7 claims
- 3782US2024425586A1Treatment of peripheral t cell lymphomaINNATE PHARMA·Filed 2024·Application pending·0 cites
- 3880US11845795B2NKp46 binding proteinsINNATE PHARMA·Filed 2019·Granted Dec 19, 2023·1 cites·12 claims
- 3980US2024124579A1Kir3dl2 binding agentsINNATE PHARMA·Filed 2023·Application pending·0 cites
- 4079US12202907B2Nucleic acids encoding and methods of producing proteins comprising antibody chainsINNATE PHARMA·Filed 2022·Granted Jan 21, 2025·0 cites·36 claims
- 4179US10736963B2Methods for detecting tissue infiltrating NK cellsINNATE PHARMA·Filed 2016·Granted Aug 11, 2020·2 cites·5 claims
- 4279US2024174748A1Variable regions for nkp46 binding proteinsINNATE PHARMA·Filed 2024·Application pending·0 cites
- 4379US2024391999A1Treatment with anti-kir3dl2 agentsINNATE PHARMA·Filed 2024·Application pending·0 cites
- 4478US11623954B2Siglec-9-neutralizing antibodiesINNATE PHARMA·Filed 2018·Granted Apr 11, 2023·1 cites·12 claims
- 4578US11377492B2NKp46 binding agentsINNATE PHARMA·Filed 2018·Granted Jul 5, 2022·1 cites·16 claims
- 4678US10132799B2Screening of conjugated antibodiesINNATE PHARMA·Filed 2013·Granted Nov 20, 2018·3 cites·22 claims
- 4778US2024141042A1MULTISPECIFIC NKp46 BINDING PROTEINSINNATE PHARMA·Filed 2023·Application pending·0 cites
- 4877US12227569B2Humanized antibodies with increased stabilityINNATE PHARMA·Filed 2021·Granted Feb 18, 2025·0 cites·14 claims
- 4977US11578136B2Compositions and methods for treating cancerINNATE PHARMA·Filed 2018·Granted Feb 14, 2023·1 cites·12 claims
- 5076US12084498B2Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphomaINNATE PHARMA·Filed 2021·Granted Sep 10, 2024·0 cites·13 claims
Showing the top 50 of 113 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →